Vision, Integrity, Expertise

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, gastrointestinal acute radiation syndrome, and melioidosis.

  • Loading stock data...

Corporate Presentation
June 14, 2017
View the presentation (pdf)
 
* * Latest News Latest News
 
* * Relevant Publications Publications
 
* * Presentations Presentations

RiVax® Correlates of Immune Protection
Serum Antibody Profiling Following Vaccination Reveals a Correlate of Immunity to Ricin Toxin
April 25, 2017
View the presentation (pdf)


Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease
March 20, 2017

Watch the presentation on YouTube


Origins of Innate Defense Regulators and Review of the SGX942 Phase 2 Study Results in Oral Mucositis Webcast
December 16, 2016
Watch the presentation on YouTube

* Presentations

RiVax® Correlates of Immune Protection
Serum Antibody Profiling Following Vaccination Reveals a Correlate of Immunity to Ricin Toxin
April 25, 2017
View the presentation (pdf)


Innate Defense Regulators: Agnostic Therapy for Antibiotic Resistant Disease
March 20, 2017

Watch the presentation on YouTube


Origins of Innate Defense Regulators and Review of the SGX942 Phase 2 Study Results in Oral Mucositis Webcast
December 16, 2016
Watch the presentation on YouTube

Our Clinical Trials

Learn more >

Partnering with Us

Learn more >